Redcare Pharmacy NV (RDC) fair value: what the stock is really worth
As of Sep 25, 2026: fair value of Redcare Pharmacy NV €13.41, price €60.50, upside -77.8%, quality 41 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Redcare Pharmacy NV for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.
How to read this chart
60‑month range €30.86 – €170.50 · fair‑value band €6.04 – €20.77 · the €60.50 price screens above the €13.41 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 27, 2026.
Follow Redcare Pharmacy in your weekly email
Every Wednesday you see whether Redcare Pharmacy is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Redcare Pharmacy NV operates the online pharmacy business in the Netherlands, Germany, Italy, Belgium, Switzerland, Austria, and France. It offers prescription and non-prescription over-the-counter pharmaceuticals, beauty and personal care products, and food supplements. The company was formerly known as Shop Apotheke Europe N.V.
Show more
Redcare Pharmacy NV operates the online pharmacy business in the Netherlands, Germany, Italy, Belgium, Switzerland, Austria, and France. It offers prescription and non-prescription over-the-counter pharmaceuticals, beauty and personal care products, and food supplements. The company was formerly known as Shop Apotheke Europe N.V. and changed its name to Redcare Pharmacy NV in June 2023. Redcare Pharmacy NV was founded in 2001 and is based in Sevenum, the Netherlands.
Stock analysis
Redcare Pharmacy NV (RDC) currently trades at €60.50, while our model-based Fair Value estimate is €13.41, implying the stock looks roughly 351.1% overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 2 models at a data quality of 92/100, which puts the evidence level at low.
Scenario range: €6.04 (bear) to €20.77 (bull), the price of €60.50 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 41/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Redcare Pharmacy NV reported revenue of €2.9B in FY2025 versus €1.1B in FY2021, a compound +29.1%/yr. Reported net income was −€37.7M in FY2025.
Key figures
Market cap €1.4B · P/S ratio 0.44 · EPS (TTM) €−1.86 · Net margin −1.3% · Return on equity −8.1% · Return on assets (EBIT) −5.1% · Operating margin −0.4% · Revenue (TTM) €3.1B.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 37 out of 100 (low confidence).
What moves the price
The share trades about 31% below its 52-week high and 96% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −78%, RDC screens richer than that median.
Fair Value models
Bear €6.04Fair Value €13.41Bull €20.77
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+24.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+34.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+24.9%
Start year 2020 (pandemic). Over 10 years: +37.1% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+39.3%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−0.1% (2020) → −0.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
News mood ⓘNews mood, the average tone of recent news (92 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Hype
Recent news coverage is unusually upbeat, far more positive than stocks are typically covered.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceutical Retailers · 59 stocks
Beats the industry median on 1/9 measures
Overall it trails its industry peers.
Valuation
Quality Score44 · Below median
Fair Value upside−77.8% · Bottom 25%
Profitability
Return on assets−0.9% · Below median
Net margin (TTM)−1.2% · Below median
Operating margin (TTM)−0.4% · Bottom 25%
Growth and dividend
Revenue growth18.4% · Top 25%
Balance sheet
Debt / equity0.57× · Highest 25%
Valuation Multiplesvs Pharmaceutical Retailers median · lower = cheaper
P/B3.38× · Priciest 25%
P/S (TTM)0.51× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 43
FUTURE (revenue growth)92· sector 19
PAST (return on equity)0· sector 22
HEALTH (low debt)72· sector 96
DIVIDEND (yield)0· sector 65
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Redcare Pharmacy NV (RDC) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of €13.41 versus a price of €60.50, about −78% upside (overvalued).
What is the fair value of RDC?
Our model-based fair value for Redcare Pharmacy NV is €13.41 (as of Sep 27, 2026), built from audited fundamentals. The current price: €60.50.
What is the quality score of RDC?
Redcare Pharmacy NV has a Quality Score of 41/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Redcare Pharmacy NV (RDC)?
Our model-based price target is the fair value of €13.41 (as of Sep 27, 2026) from 2 valuation models. Cautious scenario €6.04, optimistic scenario €20.77. It is a calculation from audited fundamentals, not an analyst target.
What is the Redcare Pharmacy NV stock forecast for 2026?
Our models put fair value at €13.41, about −78% upside versus a price of €60.50 (overvalued). Cautious scenario €6.04, optimistic scenario €20.77. The calculation is refreshed regularly with new filings.
What is the revenue of Redcare Pharmacy NV (RDC)?
Redcare Pharmacy NV reported trailing-twelve-month revenue of about €3.1B (latest available figure, as of Sep 27, 2026).
What is the intrinsic value of Redcare Pharmacy NV (RDC)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Redcare Pharmacy NV it is €13.41 per share (as of Sep 27, 2026), against a price of €60.50. It is the blended result of 2 valuation models (cash flow, earnings, asset, dividend).
Is Redcare Pharmacy NV stock overvalued or undervalued in 2026?
As of Sep 27, 2026, RDC trades above its calculated fair value: price €60.50, fair value €13.41, a gap of about −78% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of RDC?
No. The price is what the market pays today (€60.50); the fair value is what the company's own numbers justify (€13.41). For Redcare Pharmacy NV the two are €47.09 per share apart. That gap is exactly why we show both numbers side by side.
How much is Redcare Pharmacy NV worth?
The market values Redcare Pharmacy NV at about €1.4B (market capitalisation, as of Sep 27, 2026). Per share that is €60.50; our models calculate a fair value of €13.41 per share.
What do the bullish and bearish scenarios say about RDC?
Our models span a range for Redcare Pharmacy NV: cautious scenario €6.04, base €13.41, optimistic €20.77 per share (as of Sep 27, 2026, price €60.50). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Redcare Pharmacy NV (RDC)?
Balance-sheet figures for Redcare Pharmacy NV (as of Sep 27, 2026): return on equity −8.1%, debt of 0.57 per unit of equity. They feed the Quality Score of 41/100, which measures business quality independently of the share price.
How far is RDC from its 52-week high?
Redcare Pharmacy NV trades at €60.50, about 31% below its 52-week high of €87.90 and 96% above the low of €30.86 (as of Sep 25, 2026). Distance from the high says nothing about value: that is what the fair value of €13.41 is for.
Which stocks are comparable to Redcare Pharmacy NV?
From the same area (Healthcare) we also value Alibaba Health Information Technology Limited, Yifeng Pharmacy Chain Co, DaShenLin Pharmaceutical Group, LBX Pharmacy Chain Joint Stock Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Redcare Pharmacy NV stock attractive at the current price?
The data as of Sep 27, 2026: price €60.50, calculated fair value €13.41 (−78%), Quality Score 41/100, from 2 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of RDC calculated?
We run Redcare Pharmacy NV through 2 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of €13.41, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 16.1 % above its aggregate fair value. Redcare Pharmacy NV itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Redcare Pharmacy NV (RDC)?
The closing price on Sep 25, 2026 was €60.50. Our model-based fair value is €13.41, about −78% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Redcare Pharmacy NV right now?
The price sits above even our optimistic bull case (€20.77). The favourable scenario is already priced in. Weak quality (41/100) and above fair value at the same time, the margin of safety is missing on both counts. The model range is unusually wide (€6.04 to €20.77). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of Redcare Pharmacy NV
How large is the market capitalisation of Redcare Pharmacy NV (RDC)?
The market capitalisation of Redcare Pharmacy NV is €1.4B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Redcare Pharmacy NV (RDC)?
The price-to-sales ratio of Redcare Pharmacy NV is 0.44 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Redcare Pharmacy NV (RDC)?
Earnings per share at Redcare Pharmacy NV are €−1.86. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Redcare Pharmacy NV (RDC)?
The net margin of Redcare Pharmacy NV is −1.3% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Redcare Pharmacy NV (RDC)?
The return on equity (ROE) of Redcare Pharmacy NV is −8.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Redcare Pharmacy NV (RDC)?
On an EBIT basis the return on assets of Redcare Pharmacy NV is −5.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Redcare Pharmacy NV (RDC)?
The operating margin of Redcare Pharmacy NV is −0.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Redcare Pharmacy NV (RDC)?
Revenue at Redcare Pharmacy NV is growing +18.4% versus a year earlier (3y avg +34.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Redcare Pharmacy NV (RDC) generate?
The free cash flow of Redcare Pharmacy NV is −€56.3M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Redcare Pharmacy NV (RDC) carry?
The net debt of Redcare Pharmacy NV is €323M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Redcare Pharmacy NV in the live analysis
One click puts Redcare Pharmacy NV on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 27, 2026